Nautilus Biotechnology(US:NAUT)2024-10-28 21:47Financial Performance - Net loss for Q3 2024 was $16.4 million, compared to a net loss of $15.9 million in Q3 2023[4] - Operating expenses for Q3 2024 were $19.1 million, flat compared to Q3 2023[3] - The company reported a net cash used in operating activities of $44.8 million for the nine months ended September 30, 2024, compared to $37.8 million for the same period in 2023[15] Cash and Investments - Cash, cash equivalents, and investments totaled $221.2 million as of September 30, 2024[4] - Cash, cash equivalents, and restricted cash at the end of the period were $5.4 million, down from $75.1 million at the end of Q3 2023[15] Expenses - Research and development expenses for Q3 2024 were $12.3 million, up from $12.0 million in Q3 2023[13] - General and administrative expenses for Q3 2024 were $6.8 million, down from $7.1 million in Q3 2023[13] Assets and Liabilities - Total assets decreased to $259.7 million as of September 30, 2024, from $305.6 million at the end of 2023[11] - Total liabilities decreased to $36.3 million as of September 30, 2024, from $40.2 million at the end of 2023[11] Strategic Focus - The company is focused on advancing its single-molecule proteome analysis platform, which is expected to enhance research capabilities in proteomics[2]